Bayer Trasylol Being Pulled From Market After BART Trial Fails As Tourniquet
Executive Summary
Though Bayer's anti-bleeding drug Trasylol has survived the assault of observational study data and the scrutiny of two joint advisory panels, preliminary data from a randomized controlled trial has finally knocked the drug from the market